|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR-TRC-13003602 |
|
最近更新日期: Date of Last Refreshed on: |
2016-03-11 19:52:43 |
|
注册时间: Date of Registration: |
2013-07-22 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
脾不统血所致血小板减少性紫癜从脾论治的疗效机制及规律研究 |
|
Public title: |
The Research on Therapeutic Effective Mechanism and Regulation Treated from Spleen in TCM on Immune Thrombocytopenic Purpura Induced by Failure of Spleen to Control Blood |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脾不统血所致血小板减少性紫癜从脾论治的疗效机制及规律研究 |
|
Scientific title: |
The Research on Therapeutic Effective Mechanism and Regulation Treated from Spleen in TCM on Immune Thrombocytopenic Purpura Induced by Failure of Spleen to Control Blood |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈信义 |
研究负责人: |
陈信义 |
|
Applicant: |
Xinyi Chen |
Study leader: |
Xinyi Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 010 84013127 |
研究负责人电话:
Study leader's |
+86 010 84013127 |
|
申请注册联系人传真 : Applicant Fax: |
+86 010 84013127 |
研究负责人传真: Study leader's fax: |
+86 010 84013127 |
|
申请注册联系人电子邮件: Applicant E-mail: |
chenxinyi0729@126.com |
研究负责人电子邮件: Study leader's E-mail: |
chenxinyi0729@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
http://www.dzmyy.com.cn |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
http://www.dzmyy.com.cn |
|
申请注册联系人通讯地址: |
北京市东城区海运仓5号 |
研究负责人通讯地址: |
北京市东城区海运仓5号 |
|
Applicant address: |
5 Haiyuncang, Dongcheng District, Beijing |
Study leader's address: |
5 Haiyuncang, Dongcheng District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
100700 |
研究负责人邮政编码: Study leader's postcode: |
100700 |
|
申请人所在单位: |
北京中医药大学东直门医院 |
||
|
Applicant's institution: |
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine |
||
|
研究负责人所在单位: |
北京中医药大学东直门医院 |
||
|
Affiliation of the Leader: |
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
ECPJ-BDY-2013-18 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
北京中医药大学东直门医院医学伦理委员会 |
||
|
Name of the ethic committee: |
IRB of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2012-05-07 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
北京中医药大学东直门医院 |
||
|
Primary sponsor: |
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine |
||
|
研究实施负责(组长)单位地址: |
北京市东城区海运仓5号 |
||
|
Primary sponsor's address: |
5 Haiyuncang, Dongcheng District, Beijing |
||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|||
|
经费或物资来源: |
国家重点基础研究发展计划 |
||
|
Source(s) of funding: |
the National Key Basic Research Program |
||
|
研究疾病: |
免疫性血小板减少性紫癜 |
||
|
Target disease: |
Immunogenic Thrombocytopenic Purpura |
||
|
研究疾病代码: |
D69.402 |
||
|
Target disease code: |
D69.402 |
||
|
研究类型: |
干预性研究 |
||
|
Study type: |
Interventional study |
||
|
研究所处阶段: |
其它 | ||
|
Study phase: |
N/A |
||
|
研究设计: |
随机平行对照 |
||
|
Study design: |
Parallel |
||
|
研究目的: |
通过规范的临床试验,明确“脾主统血”生理特点与病理表征,研究从脾论治改善免疫性血小板减少性紫癜患者症状与止血疗效,并初步探讨效应机制。 |
||
|
Objectives of Study: |
According to clinical trials and applying basic research, the physiological and pathological characteristics of "spleen dominating blood" in TCM theory will be clarified, symptoms improvement and hemostasis effect in ITP patients will be summarized, and the ITP animal models in accordance with the TCM syndrome of “failure of the spleen to control the blood circulation” will be established as well; In addition, with the administration of different decoctions in TCM, therapeutic mechanism will be explored based on the analysis of hemostasis effect to reveal the scientific connotation of "spleen dominating blood" in TCM theory, enrich and innovate the Spleen from Zangxiang doctrine inTCM, and guide the treatment of bleeding disorders. |
||
|
药物成份或治疗方案详述: |
|
||
|
Description for medicine or protocol of treatment in detail: |
|
||
|
纳入标准: |
同时具备下列3项:①符合免疫性血小板减少性紫癜诊断标准;②符合中医证候诊断标准;③自愿受试,并签署知情同意书。 |
||
|
Inclusion criteria |
The following 3 items should be conformed simultaneously: |
||
|
排除标准: |
具备下列任意1项:①合并严重心、脑、肝、肾疾病;②精神病;③妊娠、哺乳期妇女;④有严重糖尿病、高血压并发症患者;⑤已知对受试药物(单味中药)过敏者。 |
||
|
Exclusion criteria: |
If the following any item is conformed: |
|
研究实施时间: Study execute time: |
从 From 2013-01-01 00:00:00至 To 2017-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2013-01-01 00:00:00 至 To 2017-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
简单随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Simple random |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
|
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
北京中医药大学东直门医院 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
|
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
|
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |